Decitabine

For research use only. Not for use in humans.

製品コードS1200 別名:Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR, NSC 127716

Decitabine化学構造

CAS No. 2353-33-5

Decitabine (Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR, NSC 127716) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.

サイズ 価格(税別)  
10mM (1mL in DMSO) JPY 27700
JPY 16900
JPY 30200
JPY 55100
JPY 96600
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(93)

製品安全説明書

DNA Methyltransferase阻害剤の選択性比較

生物活性

製品説明 Decitabine (Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR, NSC 127716) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.
ターゲット
DNA methylation [1]
(HL-60, KG1a cells)
体外試験

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 NVPTVWVNTnWwY4Tpc44hSXO|YYm= NI\BUZgxNjYEoN88US=> Mli4NlQhcA>? MYr3ZZRmeg>? MnvtcY9lfWyjdHXzJJRp\SCpZX7lJIV5eHKnc4Ppc44hd2ZiTVHHSU1CKG2nbXLldpM> M{KzNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKzNFgzLz5{NUGyN|A5OjxxYU6=
Eca109 MorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\6NlAvPS9{LkWvOUDPxE1? NV:1fWt5OjRxNEivO|IhcA>? M3jtZpdifGW{ NUTmU2NIcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{M{C4Nkc,OjVzMkOwPFI9N2F-
Eca109 MlLNSpVv[3Srb36gRZN{[Xl? M1HrVFAvPcLizszN NFWxNIc3NzF{L{K0JIg> MoK3e4F1\XJ? M2\U[4lvcGmkaYTzJINmdGxibXnndoF1cW:wwrC= MoHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
Eca109 NULzS4NjTnWwY4Tpc44hSXO|YYm= MXewMlXDqM7:TR?= MnjoNlQhcA>? NYr0UHhpf2G2ZYK= NUjMcGFmcW6qaXLpeJMh[2WubDDpcpZie2mxbh?= M2LhfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKzNFgzLz5{NUGyN|A5OjxxYU6=
Eca109 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFSwRY4xNjYEoN88US=> NXP5XmxPOjRiaB?= NXXvSlJSf2G2ZYK= M1XPS4lv\HWlZYOgS|IwVSCjcoLld5QhcW5idHjlJINmdGxiY4njcIU> M4PJelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKzNFgzLz5{NUGyN|A5OjxxYU6=
Eca109 MnHtSpVv[3Srb36gRZN{[Xl? NUKyS3g1OC53L{Gg{txO MXiyOEBp NYn0WndRf2G2ZYK= NYjxVIlv\GWlcnXhd4V{KGW6cILld5Nqd25ib3[gUmYu|rqEMjDhcoQhVU2SMh?= NH7VTpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyN|A5Oid-MkWxNlMxQDJ:L3G+
SW1116  NInkR3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXSwMlUwOS9{L{Wg{txO M1W4XlQ5KGh? NXPuRWZQTE2VTx?= M2Dhd4VvcGGwY3XzJJRp\SCJZX\peIlvcWJiaX7keYNm\CClZXzsJIlvcGmkaYTpc44> NH7kWHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3OFI5Pid-MkS4O|QzQDZ:L3G+
LOVO NFfyRpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXuOWhJOC53L{GvNk82KM7:TR?= NEXHSFA1QCCq NFGxWIlFVVOR NEKxcHBmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v NIT5eWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3OFI5Pid-MkS4O|QzQDZ:L3G+
SW1116  NVTQeVZbTnWwY4Tpc44hSXO|YYm= NH7JclUyOCEQvF2= NIHtTo01QCCq MkS5SG1UVw>? MWrpcoNz\WG|ZYOgeIhmKGWoZnXjeIl3\SCjdDDpcohq[mm2aX7nJGFMXCCjbnSgcXRQWiC|aXfuZYxqdmdicHH0bJdigXNiY3;tZolv\WRid3n0bEBo\W[rdHnubYI> M121fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe0Nlg3Lz5{NEi3OFI5PjxxYU6=
LOVO MYHGeY5kfGmxbjDBd5NigQ>? M1O4cVExKM7:TR?= M{PxcFQ5KGh? M4TDSGROW09? NGHlXZFqdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? NXj6XWtPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|QzQDZpPkK0PFc1Ojh4PD;hQi=>
SW1116  MX;BdI9xfG:|aYOgRZN{[Xl? MVSxNEDPxE1? Mlj0OFghcA>? MU\EUXNQ M{DvdoVvcGGwY3XzJGdm\mm2aX7pZk1qdmS3Y3XkJIFxd3C2b4Ppdy=> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
LOVO NIjnVo9CeG:ydH;zbZMhSXO|YYm= M4C1TVExKM7:TR?= NE\IN4U1QCCq NFfhN5lFVVOR MUTlcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= NIW4XZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3OFI5Pid-MkS4O|QzQDZ:L3G+
RPMI-8226 MVzBdI9xfG:|aYOgRZN{[Xl? MlyxNU8zKM7:TR?= NHTaSnE1QC95Mj:5OkBp NXrHdVVvTE2VTx?= M17EWIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
OPM-2  M3vPSWFxd3C2b4Ppd{BCe3OjeR?= MVGxM|Ih|ryP M1TFVVczNzl4L{GyNEBp MkXZSG1UVw>? M3G5Wolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NFK5Z|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizN|ExQCd-MkS4N|MyODh:L3G+
JJN3  M363NWFxd3C2b4Ppd{BCe3OjeR?= Ml;XNE42NzFizszN MmDQNlQwPDhiaB?= MknjSG1UVw>? Mm\6bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M{m2S|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN|ExQDxxYU6=
NCI-H929  MnXWRZBweHSxc3nzJGF{e2G7 MVqxM|Ih|ryP NETKSHA4Oi97Nj:xNlAhcA>? NF\OS|dFVVOR Mlq1bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M{HBTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN|ExQDxxYU6=
RPMI-8226 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELGS3QyNzJizszN NH;ONG0zPC92OD:3NkBp NY\WNGtrTE2VTx?= M{nudoFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
OPM-2  NH;XeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTwVWMyNzJizszN M4XsbFI1NzR6L{eyJIg> M3HKTmROW09? NUnEWm1n[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
JJN3  NY\m[YE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPWS5VzOC53L{Gg{txO NVXPc4c6OjRxNEivO|IhcA>? NGHhcIxFVVOR MW\h[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? M{PPU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN|ExQDxxYU6=
NCI-H929  MnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXixM|Ih|ryP Mmm2NlQwPDhxN{KgbC=> M3Swc2ROW09? NILiSpVi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= M1XCV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN|ExQDxxYU6=
HeLa NUHsb452U2mwYYPlJGF{e2G7 MkTGT4k:OTByMPMAl|UxODBizszNJIZweiCqRV7UNS=> NH\mPFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4NFA6QCd-MkS3PFAxQTh:L3G+
HeLa NXjFV2J2U2mwYYPlJGF{e2G7 NGnhUXVMcT13Lk[gxtEhOC53IN88UUBnd3JiaFXOWFI> M2m1UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{iwNFk5Lz5{NEe4NFA6QDxxYU6=
HeLa NYLWXWpsU2mwYYPlJGF{e2G7 M2nyNWtqRTJzLk[gxtEhOy5yIN88UUBnd3JiaFPOWFE> MmTiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OECwPVgoRjJ2N{iwNFk5RC:jPh?=
HeLa M374WGtqdmG|ZTDBd5NigQ>? MVTLbV0yPC52INMxJFQvPiEQvF2g[o9zKGiFTmSz M4r0elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{iwNFk5Lz5{NEe4NFA6QDxxYU6=
NB4 M4fnfWZ2dmO2aX;uJGF{e2G7 M4PLelIvPS93L{euOU8yOCEQvF2= NF;4Z5ozPCCq Mnv3SG1UVw>? NH3uN25qdmO{ZXHz[YEhfGinIHX4dJJme3Orb36gc4YheHKnY4Xyd49zKG2rUj2xNlVi M3n6W|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEi0PFcxLz5{NES4OFg4ODxxYU6=
CD4+ CD25− T  MXHGeY5kfGmxbjDBd5NigQ>? Mn3SNU82KM7:TR?= MmPIdoVlfWOnUzDncI9j[WxiRF7BJI1mfGi7bHH0bY9v M4PrXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEe2N|YxLz5{NES3OlM3ODxxYU6=
BV-173 NIm5XpNCeG:ydH;zbZMhSXO|YYm= NV7Vfox5OC5{NT:wMlUwOC55NT:xJO69VQ>? Mo\HOFgwPzJxOU[gbC=> NWP5OmpHyqCSQmO= M2Dudolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> M{HKc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
ML-1 MULBdI9xfG:|aYOgRZN{[Xl? M2PmSVAvOjVxMD61M|AvPzVxMTFOwG0> NIqxNno1QC95Mj:5OkBp NFHBO|XDqFCEUx?= NVTiRVFOcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz NXLSUmhSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
HL-60 NF3WVnJCeG:ydH;zbZMhSXO|YYm= M4C4clAvOjVxMD61M|AvPzVxMTFOwG0> NWTZN2RkPDhxN{KvPVYhcA>? MVdCpHBDWw>? NG\B[4NqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NWDXOppNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
KG-1a MlP1RZBweHSxc3nzJGF{e2G7 NEDodZQxNjJ3L{CuOU8xNjd3L{Gg{txO NVzRS4NuPDhxN{KvPVYhcA>? MYRCpHBDWw>? NIHxeGtqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NEHIN409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
BV-173 Ml33SpVv[3Srb36gRZN{[Xl? NXfvdHB2OjVyL{WwNI5O MkPuOFghcA>? MVNCpHBDWw>? MVTpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NXnkVng5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
CEM M1vUVmZ2dmO2aX;uJGF{e2G7 M{nJfVI2OC93MEDuUS=> MX20PEBp Mn33xsBRSlN? MoLjbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NEfJXoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
HL-60 NVT3RVRvTnWwY4Tpc44hSXO|YYm= NH7pZmUzPTBxNUCwcm0> M4qyZVQ5KGh? MUVCpHBDWw>? M4nGWYlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NFnEXpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
ML-1 MV7GeY5kfGmxbjDBd5NigQ>? M4H0ZlI2OC93MEDuUS=> NIPDNJo1QCCq NHrzNXDDqFCEUx?= MVLpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
DLD-1 NWXsXGh5TnWwY4Tpc44hSXO|YYm= M1H6NFI2OC93MEDuUS=> MnW4OFghcA>? M3XMWeKhWEKV Ml3H[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>? M2mwPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
HCT-116 MVTGeY5kfGmxbjDBd5NigQ>? M2PEdVI2OC93MEDuUS=> MnvCOFghcA>? MoTUxsBRSlN? M1jzcIRwKG6xdDDpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? MofKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkO2NVMoRjJ2NEKzOlE{RC:jPh?=
U937-A/E-9/14/18  MnfiRZBweHSxc3nzJGF{e2G7 MmT3NE4xOS9yLkGvNU8yOCEQvF2= MUO0PEBp MVTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYTKbJdVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNFA1PTZpPkK0N|AxPDV4PD;hQi=>
HT29 MlzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELiTpQ4OiCq NYXrN2RHUUN3ME2xOFAxyrFzN{mg{txO NGf6dXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG3NlA3OSd-MkSxO|IxPjF:L3G+
SW48 Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvkT2xWPzJiaB?= MWDJR|UxRTF3LkNCtVYvOiEQvF2= M3XTb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUeyNFYyLz5{NEG3NlA3OTxxYU6=
HCT116 MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jFRVczKGh? MlXaTWM2OD1zLkhCtVAvPCEQvF2= NF3oXYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG3NlA3OSd-MkSxO|IxPjF:L3G+
HepG2 M4rlPGZ2dmO2aX;uJGF{e2G7 MViwMlUwOSEQvF2= NGXEepUzPCCq NGHJW5NFVVOR NH;IcZl2eC2{ZXf1cIF1\WRidHjlJJJmdGG2aY\lJG9EXE5{IH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= M2rzTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
LS174T M3PKNWZ2dmO2aX;uJGF{e2G7 NGrn[pkxNjVxMTFOwG0> MYmyOEBp MWDEUXNQ NVPGSpRpdGWjZDD0c{BidiCrbnPy[YF{\SCxZjDPR3RPOiCuZY\lcJM> MmrQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNE[4O|QoRjJ2MUS2PFc1RC:jPh?=
HepG2 NULFVoY1SXCxcITvd4l{KEG|c3H5 MlHxNU8yOC9zMECg{txO NUjRWHBtPyCm NITFXI9FVVOR MVLpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NEnXemg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG0Olg4PCd-MkSxOFY5PzR:L3G+
LS174T M3v0dGFxd3C2b4Ppd{BCe3OjeR?= MkSyNU8yOC9zMECg{txO NX;FW5RHPyCm MmXDSG1UVw>? MmrUbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2Nki3OEc,OjRzNE[4O|Q9N2F-
QBC-939 M33lXWFxd3C2b4Ppd{BCe3OjeR?= NVfWWmJDOS9zMD:xNFAh|ryP MUm3JIQ> MmnSSG1UVw>? MoDwbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M{HHe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
U251 Ml;3RZBweHSxc3nzJGF{e2G7 Mlj4NU8yOC9zMECg{txO NHX3VFY4KGR? M3PJcmROW09? MUnpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYfCTWNnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFY5PzRpPkK0NVQ3QDd2PD;hQi=>
HL-60 NH3TbFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXNeWYyKM7:TR?= NUXwT5lOPDhiaB?= M4DwNolv[3KnYYPld{BIOi2yaHHz[UBk\WyuIH\yZYN1cW:w MnPYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMECzNlQoRjJ2MECwN|I1RC:jPh?=
MDA‑MB‑453 MorBSpVv[3Srb36gRZN{[Xl? NW[wdpJ6OC5{L{Gg{txO M3;xSFczKGh? NIrDRodk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> M1zuWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OES0NlI5Lz5{M{i0OFIzQDxxYU6=
HCC1569 NInpS3dHfW6ldHnvckBCe3OjeR?= NVnwR|A5OC5{L{Gg{txO MY[3NkBp NFvwNGdk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> NH[1[Zo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFIzQCd-MkO4OFQzOjh:L3G+
BT‑474 MVTGeY5kfGmxbjDBd5NigQ>? M1W5SVAvOi9zIN88US=> MkDEO|IhcA>? M1TLUINifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> NVHGc3lkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQzOjhpPkKzPFQ1OjJ6PD;hQi=>
AGS NXniW3JYSXCxcITvd4l{KEG|c3H5 NX24ZoZqPS9zMD:yNE82OCEQvF2= NHTkTIU1QMLiaNMg Mm\6SG1UVw>? Mn;KbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA> MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV6Mke4OEc,OjN3OEK3PFQ9N2F-
A549 NXTtN|V6SXCxcITvd4l{KEG|c3H5 NWG0[2RDPS9zMD:yNE82OCEQvF2= NX3GfZBsPDkEoHlCpC=> NH7uPG5FVVOR NED1eZBqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>? MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV6Mke4OEc,OjN3OEK3PFQ9N2F-
AGS  M2fKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzONZE2NzFyL{KwM|UxKM7:TR?= NHLSTGY1QMLiaNMg NXnLbJd7TE2VTx?= MmPDbY5lfWOnczDHNk9OKHCqYYPlJIFzemW|dNMg MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV6Mke4OEc,OjN3OEK3PFQ9N2F-
Kasumi-1 NH2xSmZCeG:ydH;zbZMhSXO|YYm= M1:3WlAvPSEQvF2= NVK5TZU1PDkEoHlCpC=> NH7p[Jll\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> M1T1UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEmzN|Q5Lz5{M{S5N|M1QDxxYU6=
OCI-AML3 NEX4NYlCeG:ydH;zbZMhSXO|YYm= NH;xZ2kzNjVizszN Mm\vOFjDqGkEoB?= MkHT[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= NHzTTlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5N|M1QCd-MkO0PVM{PDh:L3G+
MV4-11 M3jEXWFxd3C2b4Ppd{BCe3OjeR?= M4q2cFIvPSEQvF2= NWTMZoFzPDkEoHlCpC=> MlTH[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7M{O0PEc,OjN2OUOzOFg9N2F-
NK  NW\rdGxtS3m2b4TvfIl1gSCDc4PhfS=> MUSwMlAzNTJyIN88US=> MoO2OUBl MUHk[YNz\WG|ZYOgeIhmKGO7dH;sfZRq[yCjY4Tpeol1gSCxZjDOT{Bk\WyuczDheEBqdnSncn3l[IlifGViY3;uZ4VvfHKjdHnvcpMhemW|dXz0bY5oKGmwIHGgWU1{cGGyZXSg[I9{\eLCk4Lld5BwdnOnIHP1dpZm MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN{OEC4PEc,OjN|MkiwPFg9N2F-
NK  MoXjRZBweHSxc3nzJGF{e2G7 MnTCNE4xOi1{MDFOwG0> MVK1JIQ> M3vKS4Rm[3KnYYPlJG5MKGOnbHygdJJwdGmoZYLheIlwdiCjbnSgeoli[mmuaYT5JIF{KHSqZTDjc45k\W62cnH0bY9vKGmwY4LlZZNm\A>? MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN{OEC4PEc,OjN|MkiwPFg9N2F-
NK  M2rLOWZ2dmO2aX;uJGF{e2G7 MVewMlAyNTJyIN88US=> NGj3PJo2KGR? M4S0ToNifXOnczDofZBwdWW2aInsZZRqd25ib3[gUmsh[2WubIOgbY4h[SCmb4Pl5qCUemW|cH;ud4U> MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN{OEC4PEc,OjN|MkiwPFg9N2F-
MOLT4/DNR MUnGeY5kfGmxbjDBd5NigQ>? NHvoWo82KM7:TR?= NXvxSoVyPCCm M3rRR5Jm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v NHroTFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2NFU4OCd-MkOwOlA2PzB:L3G+
Jurkat/DOX NYPpSlJWTnWwY4Tpc44hSXO|YYm= MWm1JO69VQ>? NUfzSXdOPCCm MWDy[YR2[2W|IFHCR2IyKG2UTlGg[ZhxemW|c3nvci=> M2SzSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|ME[wOVcxLz5{M{C2NFU4ODxxYU6=
MOLT4/DNR NF7zUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzmOUDPxE1? M1LSe|Qh\A>? NVPrPWI6emWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> M2H3UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|ME[wOVcxLz5{M{C2NFU4ODxxYU6=
Jurkat/DOX NXXzVVVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[1JO69VQ>? M{DQc|Qh\A>? M3vGe5Jm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm= M2XDPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|ME[wOVcxLz5{M{C2NFU4ODxxYU6=
ccRCC  NGr5fFVCeG:ydH;zbZMhSXO|YYm= MXqwMlAyNTFyzszN M4rBOVczKGh? Ml\QSG1UVw>? NVTyPHJ[cGG|IH3pcolu[WxiZX\m[YN1KG:wIHPlcIwheHKxbHnm[ZJifGmxbh?= MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
TNBC  M3vtTWFxd3C2b4Ppd{BCe3OjeR?= M1PFTVAvODFvMUFOwG0> NGXxS3Q4OiCq M2PjbmROW09? NHy2ZpVp[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w M3zzS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEK2OFY4Lz5{MkiyOlQ3PzxxYU6=
A498 NW[1RWhTSXCxcITvd4l{KEG|c3H5 MlfuNE4xOS1zMN88US=> MXG3NkBp MVnEUXNQ NUnYTlB3cW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? NIX0VHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
KIJ265T M3TOcGFxd3C2b4Ppd{BCe3OjeR?= NXjrXY54OC5yMT2xNO69VQ>? NUH0ZY5YPzJiaB?= Mn6ySG1UVw>? NGrIdFNqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv MmfxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6Mk[0OlcoRjJ{OEK2OFY4RC:jPh?=
MDA-231 NWfUcGlNSXCxcITvd4l{KEG|c3H5 MknWNE4xOS1zMN88US=> NF\NSlQ4OiCq MVrEUXNQ NYnNd|ZvcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? NYWxcpZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NlY1PjdpPkKyPFI3PDZ5PD;hQi=>
BT-20 NYPGUFJQSXCxcITvd4l{KEG|c3H5 NUfMUFlnOC5yMT2xNO69VQ>? NEjHdXA4OiCq NY\wTVR{TE2VTx?= MlO3bY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> NUjnOHQ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NlY1PjdpPkKyPFI3PDZ5PD;hQi=>
U937 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nw[lUuOjBizszN MYCyOE81QC95MjDo MX3pcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy M{e2b|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{[3NFIyLz5{Mke2O|AzOTxxYU6=
HL60 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLZXJI2NTJyIN88US=> NGnNZZEzPC92OD:3NkBp M1\Hbolv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NWn1OXIxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3OlcxOjFpPkKyO|Y4ODJzPD;hQi=>
U937 M4q1R2Fxd3C2b4Ppd{BCe3OjeR?= NFnNUW4yPSEQvF2= M{TKVFI1NzR6L{eyJIg> M3qw[4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MlnVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5NkewNlEoRjJ{N{[3NFIyRC:jPh?=
HL60 M4HveGFxd3C2b4Ppd{BCe3OjeR?= NYLw[mxSOTVizszN M1fzRVI1NzR6L{eyJIg> NHGxZYZqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NVXaZWlnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3OlcxOjFpPkKyO|Y4ODJzPD;hQi=>
LS411N  M{DCNmFxd3C2b4Ppd{BCe3OjeR?= NIrMRVkxNjVizszN MVO3NkBp MXzpcoNz\WG|ZYOgSoF{KG2UTlGgcIV3\Wx? NVXXTHhQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0OlE3QTVpPkKyOFYyPjl3PD;hQi=>
MDA-MB-231 NF;MemNCeG:ydH;zbZMhSXO|YYm= NIC5enAyOCEQvF2= NFfseVE1QCCq NXTEUoh3emWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTh6N{[5O{c,OjF6OEe2PVc9N2F-
MCF-7  NEHLTG5CeG:ydH;zbZMhSXO|YYm= Mn3ONVAh|ryP NU\yWHJsPDhiaB?= MYfy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1LtNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEi3Olk4Lz5{MUi4O|Y6PzxxYU6=
A375 M1;r[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M32ySVAvPSEQvF2= NX\nT4s3OS93L{ig[C=> NVf5[ohUcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NVj3T3VvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PVY3OjJpPkKxO|k3PjJ{PD;hQi=>
SKMEL1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYKwMlUh|ryP NGLVdVIyNzVxODDk NYPCVnNZcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
SKMEL3 NVnTcZBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInsd2gxNjVizszN MX:xM|UwQCCm M{KzSYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MkjjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OU[2NlIoRjJzN{m2OlIzRC:jPh?=
SKMEL28 NGjBU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33pXFAvPSEQvF2= NELLUI8yNzVxODDk NXXq[HRucW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= M4HDPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{m2OlIzLz5{MUe5OlYzOjxxYU6=
MeWo Mn3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnq3NE42KM7:TR?= NFi4bIsyNzVxODDk NUPMUYgzcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
B16 NHfrdIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnqNE42KM7:TR?= NYH0TZpZOS93L{ig[C=> M2jMUYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| Mmn0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OU[2NlIoRjJzN{m2OlIzRC:jPh?=
Ly 1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHNNlQhcA>? M1TIVmlEPTB;Nz6zJO69VQ>? NV7h[4VGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Ly 7 NIf6bY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmH4NlQhcA>? NFvB[YNKSzVyPUGwMlch|ryP NFfwZms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Su-DHL6 M3fjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXyyOEBp NIX5eGpKSzVy78{eNlAh|ryP Ml;MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 10 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fEflI1KGh? M1XnVWlEPTExvK6yNEDPxE1? NIPqS4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
RIVA MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojUNlQhcA>? MVPJR|Ux97zgMkCg{txO M33qOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Su-DHL2 MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPSOWozPCCq NVTV[3ZuUUN3MP-8olIxKM7:TR?= M3vkNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 1 NF\kfI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jMZlQ5KGh? NF[ydZdKSzVyPUCuN|Qh|ryP MoL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 7 NIrDZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGexe5M1QCCq Mm\aTWM2OD1yLkCyOUDPxE1? NXvJ[ZB2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Su-DHL6 M2fs[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXq0PEBp MU\JR|Ux97zgMkCg{txO NE\HUVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Ly 10 NX;JWZhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHlOFghcA>? NUXIVm5OUUN3ME2xMlgh|ryP NXLXXIhbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
RIVA NHvXbWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHj3UlY1QCCq MmGzTWM2OO,:nkKwJO69VQ>? NYXrW5VSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Su-DHL2 M4qwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPsTZNEPDhiaB?= MknrTWM2OD1zNz60JO69VQ>? M2rKRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 1 NGX0VGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{SyZ|czKGh? MU\JR|UxRTBwMEGg{txO M4DaTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 7 NH;DfoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULQTZh2PzJiaB?= NEj3[ldKSzVyPUCuNFE5KM7:TR?= NXPx[GFkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Su-DHL6 NIraOnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fHVVczKGh? NWDPPGUyUUN3ME2xMlYh|ryP M33rNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 10 MlnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13ie|czKGh? MVHJR|UxRTFwMjFOwG0> Mn3MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
RIVA MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXzPW84OiCq NXLRZ|JbUUN3MP-8olIxKM7:TR?= M4\4R|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Su-DHL2 M2X6dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHHW5I4OiCq NWG4e2N3UUN3ME2xNU4zKM7:TR?= M4PHe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
U373-MAGI MmjnRY51cX[rcnHsJIF{e2G7 MXuwMlI2KHSxIEigeW0> MV6yJJRwKDd{IHjydy=> MlfXRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgWnNXNUdicIPleYRwfHmyZXSgTGlXNTFiTly0MVMhcW6oZXP0[YQhcW5iaIXtZY4hXTN5Mz3NRWdKKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDVOU1o[WdibHX2[Ywh[XRiMD6yOUB1dyB6IIXNJIFnfGW{IEKgeI8hPzJiaILzJIJ6KHGSQ2KgcYV1cG:m MlzjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUeyOlAoRjJ5MUG3NlYxRC:jPh?=
U373-MAGI M2HLcWFvfGm4aYLhcEBie3OjeR?= NFjUW40xNjJ3IITvJFghfU1? M3;EeVIhfG9iN{KgbJJ{ MoiyRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgWnNXNUdicIPleYRwfHmyZXSgTGlXNTFiTly0MVMhcW6oZXP0[YQhcW5iaIXtZY4hXTN5Mz3NRWdKKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDnZYchdGW4ZXygZZQhOC5{NTD0c{A5KHWPIHHmeIVzKDJidH:gO|IhcHK|IHL5JJFRS1JibXX0bI9l M4XMdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO|I3ODxxYU6=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
Survivin / Bcl-2 / p53 / c-Myc / DNMT1; 

PubMed: 26384351     


HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells.

p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; 

PubMed: 25762617     


Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations.

phospho-p38 / p38 / phospho-NFκB / NFκB; 

PubMed: 26617834     


Decitabine suppressed the phosphorylation of p38 and NF-κB.

p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; 

PubMed: 26692933     


DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments.

E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; 

PubMed: 28152502     


The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.

26384351 25762617 26617834 26692933 28152502
Immunofluorescence
DNMT1; 

PubMed: 21303982     


Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain).

E-cadherin / MMP-9; 

PubMed: 28152502     


Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC. 

21303982 28152502
Growth inhibition assay
Cell viability; 

PubMed: 26384351     


Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.

26384351
体内試験 In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
- 合併

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
細胞試験: [1]
- 合併
  • 細胞株: HL-60 and KG1a
  • 濃度: 0-500 nM
  • 反応時間: 96 hours
  • 実験の流れ: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (参考用のみ)
動物試験:[2]
- 合併
  • 動物モデル: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • 投薬量: ≤2.5 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
water
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 228.21
化学式

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
別名 Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR, NSC 127716
Smiles C1C(C(OC1N2C=NC(=NC2=O)N)CO)O

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04086238 Completed Drug: Decitabine Healthy EpiDestiny Inc. October 8 2019 Phase 1
NCT04113616 Recruiting Drug: KRT-232|Drug: Cytarabine|Drug: Decitabine Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN) Kartos Therapeutics Inc. September 25 2019 Phase 1|Phase 2
NCT03875287 Recruiting Drug: Decitabine|Drug: Cedazuridine Solid Tumor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals Inc. April 17 2019 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Is S1200 a racemic mixture or a monomer?

  • 回答:

    S1200 is R form

DNA Methyltransferaseシグナル伝達経路

Tags: Decitabineを買う | Decitabine ic50 | Decitabine供給者 | Decitabineを購入する | Decitabine費用 | Decitabine生産者 | オーダーDecitabine | Decitabine化学構造 | Decitabine分子量 | Decitabine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID